Universal Ibogaine Inc. (TSXV:IBO)

Market Cap	6.17M
Revenue (ttm)	1.90M
Net Income (ttm)	-2.27M
Shares Out	308.61M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,040
Average Volume	n/a
Open	0.0200
Previous Close	0.0250
Day's Range	0.0200 - 0.0250
52-Week Range	0.0050 - 0.0300
Beta	6.91
RSI	58.07
Earnings Date	Mar 28, 2025

About Universal Ibogaine

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nicholas Karos
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: IBO

Financial Performance

In 2024, Universal Ibogaine's revenue was 2.33 million, an increase of 126.32% compared to the previous year's 1.03 million. Losses were -2.05 million, -14.17% less than in 2023.